Bristol-Myers Squibb entered a partnership with ConcertAI to use the latter’s real-world data and artificial intelligence (AI) insights platform as it looks to speed development of new drugs for cancer, the companies reported Thursday. Jeff Conklin, head of business insights and analytics at Bristol-Myers Squibb, said the deal “reinforces our commitment to pursue data science to accelerate disease insights, advance novel study concepts and achieve precision in treatment.”